Physician profile
Daniel V Catenacci
NPI 1467609537
$161,042.25
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $37K · 2021: $80K · 2022: $2,177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37,678.29 | 2019-2021 | |
| Lilly USA, LLC | $34,711.67 | 2019-2021 | |
| Daiichi Sankyo INC. | $13,876.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $11,175.00 | 2020-2021 | |
| Genentech USA, INC. | $9,657.23 | 2019 | |
| Eli Lilly and Company | $9,112.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $8,103.38 | 2021 | |
| Seagen INC. | $7,185.00 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $7,074.00 | 2021 | |
| F. Hoffmann-La Roche Ag | $5,870.00 | 2020-2021 | |
| Astrazeneca Uk Limited | $4,110.00 | 2021 | |
| Incyte Corporation | $3,254.00 | 2019-2021 | |
| Astellas Pharma US INC | $2,667.50 | 2021 | |
| Roche Diagnostics International Ltd | $2,475.00 | 2021 | |
| Servier Pharmaceuticals LLC | $1,970.52 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $1,680.00 | 2021 | |
| Amgen INC. | $324.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.78 | 2022 |
6 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Catenacci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.